I501, I509, I110, I130 and I132. For each hospitalization, a weighted disease related group (DRG) cost (€ , 2012) was calculated. No discount rate was applied. Results: If 100,000 patients are treated with sacubitril/valsartan, about 4,500 deaths and 39,000 hospitalizations may be avoided over 5 years. From a DRG perspective those avoided hospitalizations may lead to cost savings of about 130m€ . From a hospital budget perspective this may lead to a 10m€ avoided budget deficit. Indeed, there was a difference between weighted DRG cost (3,329€ ) and costs incurred in the national cost study (Etude Nationale de Coûts à méthodologie Commune) for HF hospitalizations (3,591€ ). The budget deficit corresponds to this difference multiplied by the number of avoided hospitalizations. ConClusions: From the French hospital perspective, sacubitril/valsartan introduction in HF treatment strategy has the potential to generate substantial savings and to minimize budget deficit. An analysis from a broader perspective (including drugs costs) should be conducted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.